Although there has not yet been successful clinical application of agents targeting KRAS activation, recent studies have suggested drugs that target molecules downstream of KRAS signaling, such as MEK, as novel therapeutic targets for the treatment of KRAS‐activated carcinomas.54 The gene discussed is MAP2K7; the disease is carcinoma.